Rodrigo-Gisbert, Marc
García-Tornel, Alvaro
Requena, Manuel
Vielba-Gómez, Isabel
Bashir, Saima
Rubiera, Marta
De Dios Lascuevas, Marta
Olivé-Gadea, Marta
Piñana, Carlos
Rizzo, Federica
Muchada, Marian
Rodriguez-Villatoro, Noelia
Rodríguez-Luna, David
Juega, Jesus
Pagola, Jorge
Hernández, David
Molina, Carlos A.
Terceño, Mikel
Tomasello, Alejandro
Ribo, Marc http://orcid.org/0000-0001-6944-6383
Funding for this research was provided by:
Fundació Institut de Recerca Hospital Universitari Vall d’Hebron (Carles Margarit, 2023 edition)
Article History
Received: 15 September 2023
Accepted: 31 January 2024
First Online: 5 February 2024
Competing interests
: Dr Molina reported receiving personal fees from AstraZeneca for consultant services outside the submitted work. Dr Tomasello reported receiving personal fees from Anaconda Biomed, Balt, Medtronic, Perflow, and Stryker outside the submitted work. Dr Ribo reported receiving personal fees from Anaconda Biomed, AptaTargets, Cerenovus, Medtronic, Methinks, Philips, Sanofi, Stryker, Balt, and Rapid AI outside the submitted work; he has a modest ownership of NoraHealth. The other authors report no conflicts. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.